Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

The deal gives the Swiss pharma access to an experimental amylin-targeting treatment it will test in combination with drugs it acquired from Carmot.

Roche partnered with Zealand Pharma to license an experimental weight loss drug for $1.65 billion upfront, expanding its obesity pipeline.

BERLIN (Reuters) -Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wednesday.

Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma. The Swiss pharmaceutical company will collaborate with Zealand on petrelintide,